Tokyo Tape
Sign in
← Fuso Pharmaceutical Industries

Annual report

4538.TEDINET S100YHSC
Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 88
MetricValuePeriodScopeSource row
Revenue¥62.3bn2025-04-01 → 2026-03-31StandaloneNet sales
Revenue¥60.6bn2024-04-01 → 2025-03-31StandaloneNet sales
Revenue¥55.4bn2023-04-01 → 2024-03-31vStandaloneNet sales (5-year summary)
Revenue¥51.0bn2022-04-01 → 2023-03-31vStandaloneNet sales (5-year summary)
Revenue¥49.6bn2021-04-01 → 2022-03-31vStandaloneNet sales (5-year summary)
Operating income¥2.6bn2025-04-01 → 2026-03-31StandaloneOperating income
Operating income¥4.1bn2024-04-01 → 2025-03-31StandaloneOperating income
Ordinary income¥2.3bn2025-04-01 → 2026-03-31StandaloneOrdinary income
Ordinary income¥3.8bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥1.9bn2023-04-01 → 2024-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥2.2bn2022-04-01 → 2023-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥2.0bn2021-04-01 → 2022-03-31vStandaloneOrdinary income loss (5-year summary)
Profit before tax¥2.4bn2025-04-01 → 2026-03-31StandaloneIncome before income taxes
Profit before tax−¥5.0bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Net income¥2.0bn2025-04-01 → 2026-03-31StandaloneProfit loss
Net income−¥3.3bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥1.4bn2023-04-01 → 2024-03-31vStandaloneNet income loss (5-year summary)
Net income¥1.6bn2022-04-01 → 2023-03-31vStandaloneNet income loss (5-year summary)
Net income¥1.5bn2021-04-01 → 2022-03-31vStandaloneNet income loss (5-year summary)
Total assets¥90.3bnat 2026-03-31StandaloneAssets
Total assets¥81.7bnat 2025-03-31StandaloneAssets
Total assets¥75.8bnat 2024-03-31vStandaloneTotal assets (5-year summary)
Total assets¥72.5bnat 2023-03-31vStandaloneTotal assets (5-year summary)
Total assets¥69.3bnat 2022-03-31vStandaloneTotal assets (5-year summary)
Total liabilities¥55.3bnat 2026-03-31StandaloneLiabilities
Total liabilities¥48.7bnat 2025-03-31StandaloneLiabilities
Net assets / equity¥35.1bnat 2026-03-31StandaloneNet assets
Net assets / equity¥33.0bnat 2025-03-31StandaloneNet assets
Net assets / equity¥36.7bnat 2024-03-31vStandaloneNet assets
Net assets / equity¥35.6bnat 2023-03-31vStandaloneNet assets (5-year summary)
Net assets / equity¥34.5bnat 2022-03-31vStandaloneNet assets (5-year summary)
Cash and deposits¥4.8bnat 2026-03-31StandaloneCash and deposits
Cash and deposits¥6.3bnat 2025-03-31StandaloneCash and deposits
Cash & equivalents¥4.8bnat 2026-03-31StandaloneCash and cash equivalents
Cash & equivalents¥6.3bnat 2025-03-31StandaloneCash and cash equivalents
Cash & equivalents¥5.1bnat 2024-03-31vStandaloneCash and cash equivalents
Cash & equivalents¥8.0bnat 2023-03-31vStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥7.3bnat 2022-03-31vStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥6.2bn2025-04-01 → 2026-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥3.3bn2024-04-01 → 2025-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥627m2023-04-01 → 2024-03-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.9bn2022-04-01 → 2023-03-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.5bn2021-04-01 → 2022-03-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥1.5bn2025-04-01 → 2026-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥3.2bn2024-04-01 → 2025-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥3.5bn2023-04-01 → 2024-03-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.4bn2022-04-01 → 2023-03-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.6bn2021-04-01 → 2022-03-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥6.3bn2025-04-01 → 2026-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥7.6bn2024-04-01 → 2025-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥14m2023-04-01 → 2024-03-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥813m2022-04-01 → 2023-03-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.7bn2021-04-01 → 2022-03-31vStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥235.632025-04-01 → 2026-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-384.952024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥159.982023-04-01 → 2024-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥183.072022-04-01 → 2023-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥169.092021-04-01 → 2022-03-31vStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥902025-04-01 → 2026-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥822024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥702023-04-01 → 2024-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥702022-04-01 → 2023-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥602021-04-01 → 2022-03-31vStandaloneDividend paid per share (5-year summary)
Net assets per share¥4,106.51at 2026-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥3,869.1at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥4,290.55at 2024-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥4,064.76at 2023-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥3,936.7at 2022-03-31vStandaloneNet assets per share (5-year summary)
Equity ratio38.8%at 2026-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio40.4%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio48.4%at 2024-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio49.2%at 2023-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio49.8%at 2022-03-31vStandaloneEquity to asset ratio (5-year summary)
ROE5.9%2025-04-01 → 2026-03-31StandaloneRate of return on equity (5-year summary)
ROE-9.4%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE3.8%2023-04-01 → 2024-03-31vStandaloneRate of return on equity (5-year summary)
ROE4.6%2022-04-01 → 2023-03-31vStandaloneRate of return on equity (5-year summary)
ROE4.3%2021-04-01 → 2022-03-31vStandaloneRate of return on equity (5-year summary)
Shares issued9,451,169at 2026-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2024-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2023-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2022-03-31vStandaloneTotal number of issued shares (5-year summary)
Employees1,374at 2026-03-31StandaloneNumber of employees
Employees1,340at 2025-03-31StandaloneNumber of employees
Employees1,307at 2024-03-31vStandaloneNumber of employees
Employees1,314at 2023-03-31vStandaloneNumber of employees
Employees1,344at 2022-03-31vStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 2
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2026-03-311268 pure
Real Estate Businessreportable segmentemployeesat 2026-03-311 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,103
ItemContextValueUnit
Packing and transportation expenses sgaCurrentYearDuration_NonConsolidatedMember2328000000JPY
Salaries sgaPrior1YearDuration_NonConsolidatedMember2363000000JPY
Salaries sgaCurrentYearDuration_NonConsolidatedMember2584000000JPY
Provision for bonuses sgaPrior1YearDuration_NonConsolidatedMember408000000JPY
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember367000000JPY
Provision for directors bonuses sgaPrior1YearDuration_NonConsolidatedMember35000000JPY
Provision for directors bonuses sgaCurrentYearDuration_NonConsolidatedMember25000000JPY
Provision for directors retirement benefits sgaPrior1YearDuration_NonConsolidatedMember8000000JPY
Provision for directors retirement benefits sgaCurrentYearDuration_NonConsolidatedMember17000000JPY
Retirement benefit expenses sgaPrior1YearDuration_NonConsolidatedMember184000000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember162000000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember342000000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember572000000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember1718000000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember2013000000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodPrior1YearDuration_NonConsolidatedMember1718000000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodCurrentYearDuration_NonConsolidatedMember2013000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2026-06-23
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第103期(自　2025年４月１日　至　2026年３月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)扶桑薬品工業株式会社
Company name in english cover pageFilingDateInstantFuso Pharmaceutical Industries, Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　戸　田　幹　雄
Address of registered headquarter cover pageFilingDateInstantText · Plus
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)06-6969-1131(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)上席執行役員　総務本部長総務部長(兼)経理部長古　市　晴　彦
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町二丁目４番５号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03-5203-7101(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)執行役員　営業本部東京第一支店長(兼)東京事務所長田　島　潔
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00953
Fund codeFilingDateInstant－
Security codeFilingDateInstant45380
Filer name in japaneseFilingDateInstant
Original text (Japanese)扶桑薬品工業株式会社
Filer name in englishFilingDateInstantFuso Pharmaceutical Industries, Ltd.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Current fiscal year start dateFilingDateInstant2025-04-01
Current period end dateFilingDateInstant2026-03-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2026-03-31
Previous fiscal year start dateFilingDateInstant2024-04-01

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2025-03-31pass rounding
balance sheet identitynon_consolidated 2026-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2026-03-31pass
statement vs summary · operating cash flownon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flownon_consolidated 2025-04-01/2026-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2025-04-01/2026-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2026-03-31pass